The bank initiated coverage at a buy rating.
Category: Uncategorized
Buy this biopharmaceutical stock that can rally 25%, says RBC Capital Markets
The firm initiated coverage at an outperform rating.
Wall Street firms say this obesity beneficiary is a buy, with one calling for more than 85% upside
Two firms initiated coverage with buy ratings on Tuesday.
Tuesday’s big stock stories: What’s likely to move the market in the next trading session
The S&P 500 made a failed attempt at a comeback on Monday, ultimately logging its third losing session. Here’s what CNBC is watching going into Tuesday.
Berkshire Hathaway stock will see ‘higher highs’ over the coming months, says technical analyst Ari Wald
Oppenheimer’s Ari Wald gave his take on Berkshire Hathaway and two other market movers.
Tax refunds are currently averaging $2,169 — How it might affect these consumer stocks
The heftiest refunds are still to come, and that could provide a tailwind for a slate of consumer-focused stocks.
Analysts raise Berkshire Hathaway targets after ‘stellar’ Geico turnaround and mild wildfire effects
Berkshire Hathaway’s strong quarterly earnings report prompted a slew of Wall Street analysts to raise their price targets on the conglomerate’s stock.
Momentum stocks like Palantir and Goldman are cracking. What the charts say will happen next
Katie Stockton breaks down the charts on Palantir, Goldman and a main momentum ETF.
Why Walmart’s stock may continue to struggle and how to capitalize on it
Mike Khouw describes why the world’s largest retailer may struggle from here.
One-time market favorite Palantir drops 9% on Monday and is now down nearly 30% from high
The stock is on pace for its fourth straight losing session.